[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertensive-emergency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertensive-emergency":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100632259",false,"NCT07511361","Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","KARDINAL-ASH","Key Inclusion Criteria:\n\n* Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg\u002Fm2\n* Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and\u002For treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and\u002For DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization\n* At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg\n* Presence of established cardiovascular or renal disease\n\nKey Exclusion Criteria:\n\n* Has known history of secondary hypertension\n* Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)\n* Has abnormal thyroid function with clinical significance\n* Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening\n* History of and\u002For obvious clinical signs or symptoms of cirrhosis or other significant liver disease\n* Alanine aminotransferase or aspartate aminotransferase \\>2 x upper limit of normal\n* Most recent hospitalization was for non-cardiovascular or non-renal conditions","ALL","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.",[26,27,28,29],"Hypertension","Acute Severe Hypertension","Hypertensive Emergency","Hypertensive Urgency","RECRUITING","2026-06-29",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2026-06-23",{"date":38,"type":20},"2027-02",{"name":40,"class":41},"Kardigan, Inc.","INDUSTRY",8,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100538120","NCT06286696","Optic Nerve Sheath Diameter in Hypertensive Emergency","Point-of-care Ultrasound of Optic Nerve Sheath Diameter in Suspected Hypertensive Emergency","OpticUS","Inclusion Criteria:\n\n* ≥ 18 years old\n* Any patient presenting to the emergency department (ED) with suspected hypertensive emergency i.e.: blood pressure of \\> 200 millimetres of mercury (mmHg) systolic and\u002For \\> 120 mmHg diastolic\n\nExclusion Criteria:\n\n* Patients with preexisting optic nerve head changes such as glaucoma, pre-existing retinal artery\u002Fvein occlusions or any other condition that makes assessment of the fundi impossible.\n* Primary neurological cause of hypertension: ischemic cerebrovascular incident",{"count":51,"type":20},375,"OBSERVATIONAL","This prospective observational study investigates the potential of point-of-care ultrasonography of the optic nerve sheath diameter (ONSD) to rule out papilledema in patients with suspected hypertensive emergency. The primary focus is on assessing ONSD sensitivity in identifying papilledema (hypertensive retinopathy grade 4), while secondary endpoints include hypertensive retinopathy grade 3, hypertensive encephalopathy, and the need for intravenous rapid-acting medications to lower elevated blood pressure. This study aims to determine the diagnostic characteristics of this procedure for the diagnosis of hypertensive retinopathy, thus assessing its potential as a screening tool to rule out hypertensive retinopathy by the acute internal medicine doctor.",[28,55,26],"Papilledema","NOT_YET_RECRUITING","2024-10-08",{"date":59,"type":34},"2024-10-09",{"date":61,"type":20},"2024-11-01",{"date":63,"type":20},"2026-12-01",{"name":65,"class":66},"Leiden University Medical Center","OTHER",""]